FDA issues labeling changes for efavirenz.
González-Lahoz
Juan
J
D000480:Alkynes; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D048588:Benzoxazines; D003521:Cyclopropanes; D004348:Drug Labeling; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D010078:Oxazines / Q000009:adverse effects* / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D010078:Oxazines; C098320:efavirenz